Application Performance of Mumps Vaccine in Mumps
DOI:
https://doi.org/10.62051/571wxe66Keywords:
Mumps; Mumps vaccine; Application.Abstract
Mumps a highly contagious disease, and it is caused by mumps virus. This research analyzed analyzes the research progress of mumps vaccine, and discussed the main problems faced by mumps vaccine. The live attenuated mumps vaccine has been used in most countries and regions for nearly 50 years since its introduction. Although mumps vaccination was able to greatly reduce the incidence of mumps in the past, in recent years there are many cases of mumps around the world, indicating a tendency for mumps disease to recrect. The reason is prolonged use of the mumps vaccine has led to some problems. The main problem is the vaccine is not effective enough, and the immune effect become weaker with time. Because mumps is highly contagious and can cause many very serious sequelae, so it is important to prevent mumps disease. The most useful way to control mumps disease is still mumps vaccine. Changing the injection schedule, increasing the number of injections, and designing new vaccines with other genotypes mumps virus as vaccine strains may solve the main problem faced by the current mumps vaccine.
Downloads
References
[1] World Health Organization, Mumps virus vaccines, Weekly Epidemiological Record=Relevé épidémiologique hebdomadaire 82 (7) (2007) 51-60.
[2] N. Litman, S. G. Baum, Mumps Virus. In Principles and Practice of Infectious Diseases, 7th edn, GL Mandell, JE Bennett, R Donlin (eds). Churchill Livingstone: Philadelphia, PA, 2010; 2201–2206.
[3] S. Rubin, M. Eckhaus, L. J. Rennick, et al. Molecular biology, pathogenesis and pathology of mumps virus, The Journal of pathology 235 (2) (2015) 242-252.
[4] C. D. Johnson, E. W. Goodpasture, An investigation of the etiology of mumps, The Journal of experimental medicine 59 (1) (1934) 1.
[5] G. C. Brown, J. V. Baublis, T. P. O'Leary, Development and duration of mumps fluorescent antibodies in various immunoglobulin fractions of human serum, The Journal of Immunology 104 (1) (1970) 86-94.
[6] A. Hviid, S. Rubin, K. Mühlemann, Mumps, The Lancet 371 (9616) (2008) 932-944.
[7] S. B. Su, H. L. Chang, K. T. Chen, Current status of mumps virus infection: epidemiology, pathogenesis, and vaccine, International journal of environmental research and public health 17 (5) (2020) 1686.
[8] S. Schwarzer, S. Reibel, A. B. Lang, et al. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines, Vaccine 16 (2-3) (1998) 298-304.
[9] I. Davidkin, M. Valle, I. Julkunen, Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up, Vaccine 13 (16) (1995) 1617-1622.
[10] X. Sun, F. Tang, Y. Hu, et al. High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China, Human Vaccines & Immunotherapeutics 16 (7) (2020) 1738-1742.
[11] P. Kaaijk, A. J. Wijmenga-Monsuur, M. A. van Houten, et al. A third dose of measles-mumps-rubella vaccine to improve immunity against mumps in young adults, The Journal of Infectious Diseases 221 (6) (2020) 902-909.
[12] J. Hiebert, M. Saboui, J. R. Frost, et al. Mumps resurgence in a highly vaccinated population: Insights gained from surveillance in Canada, 2002–2020, Vaccine 41 (25) (2023) 3728-3739.
[13] K. Briggs, C. Kirby, A. C. Beavis, et al. Immunogenicity of mumps virus genotype G vaccine candidates in Jeryl Lynn-immunized mice, Journal of Virology 96 (8) (2022) e01983-21.
[14] H. Won, A. R. Kim, G. T. Chung, et al. Improved immunogenicity of the inactivated F genotype mumps vaccine against diverse circulating mumps viruses in mice, Vaccines 11 (1) (2023) 106.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
